Uncategorized-EN
SPAGN Annual Conference 2026 Highlights ✨
Photos: Uli Deck A Global Community United by Hope and Collaboration The SPAGN Annual Conference 2026, held in Stockholm, Sweden at Karolinska University Hospital and Elite Hotel Carolina Tower, once again demonstrated the strength, warmth, and determination of the global sarcoma community. Bringing together patients, advocates, healthcare professionals, researchers, and industry partners from around the…
Read MoreBy bike from Berlin to the Taj Mahal: Young Ewing sarcoma survivor starts charity tour
At the age of 22, John Müller was diagnosed with an Ewing sarcoma, followed by ten months of multimodal therapy. Three years later, he plans to set off by bicycle from Germany to India. His goal: to raise awareness of Ewing sarcomas and to mobilize donations for an emergency fund for sarcoma patients, particularly adolescents and young adults (AYA). Shortly before the start of his journey, John spoke with Voices of Sarcoma.
Read MoreUSA: Rutledge Cancer Foundation
USA: Rutledge Cancer Foundation Back to members Organisation Profile Patient Support and Resources They fund programs and provide resources to meet the emotional and physical needs of AYA patients with cancer — offering support where it’s needed most. About the Research They Fund They focus on funding research and clinical trials…
Read MoreKey Take-Aways for Patients from EMSOS 2026
EMSOS is a leading European society focused on musculoskeletal oncology. Each year, the congress brings specialists together to share the latest insights, treatments, and research results. The 2026 edition took place in Portugal. What also stood out was that the congress was not only about doctors and treating specialists. Researchers, students, psychologists, and other healthcare…
Read MoreROGER EXPLORES… Immunotherapy
Immunotherapy has transformed cancer treatment in recent years by harnessing the body’s own immune system to identify and fight tumour cells. But, its application in the treatment of sarcomas is still limited. Roger Wilson explains here some basics of immunotherapy, the implications for sarcoma patients and points to some studies. A Beginners’ guide on immunotherapy for sarcoma patients.
Read MoreTebentafusp in HLA-A*02:01 Positive Patients with advanced Clear Cell Sarcoma
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma Agent: Tebentafusp vs. Physician’s choice Phase II Status Recruiting Sponsor Sarcoma Alliance for Research through Collaboration (SARC) For further information please also consult https://clinicaltrials.gov/study/NCT06942442 This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell…
Read MoreStrateGIST 3
StrateGIST 3: IDRX-42 vs. Sunitinib in patients with metastatic or unresectable GIST, after first-line Imatinib treatment. Agent: IDRX-42 Sunitinib Phase III Status Recruiting Sponsor GlaxoSmithKline For further information please consult https://clinicaltrials.gov/study/NCT07218926 The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating…
Read MoreMaking Expert Knowledge Accessible: New Lay Summary of Desmoid Tumor Consensus
SPAGN has released a new lay summary of the international expert consensus on the management of desmoid tumors, originally published in JAMA Oncology in 2024. While the scientific article was written for clinicians and researchers, the new summary translates its key messages into clear, accessible language for patients, families, and advocates. Highly technical medical publications…
Read MoreShare Your Experience: Contribute to the CURE ID Sarcoma
Patients, care partners, and healthcare providers are invited to share their experiences through the Sarcoma Treatment Survey on CURE ID. CURE ID is a free website and mobile app developed by the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) in collaboration with several patient and clinical organizations. The platform…
Read MoreGD2-SADA: 177Lu-DOTA
GD2-SADA: 177Lu-DOTA in GD2-Positive Tumors Agent: GD2-SADA, 177Lu-DOTA Phase I Status Recruiting Sponsor Y-mAbs Therapeutics For further information please also consult https://clinicaltrials.gov/study/NCT05130255 Patients with Sarcoma, Small Cell Lung Cancer, High Risk Neuroblastoma, or Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex. The treatment uses a two-step approach (pre-targeted radioimmunotherapy). GD2-SADA – a specially designed…
Read More